Table 1.

Currently FDA-approved direct-acting antiviral agents

NS5B polymerase inhibitors	NS3/4A protease inhibitors	NS5A inhibitors
Sofosbuvir	Simeprevir	Daclatasvir
Dasabuvir	Paritaprevir Grazoprevir	Ledipasvir Ombitasvir Elbasvir

FDA, U.S Food and Drug Administration.